Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2025-2737

Published: 2025

Journal Articles

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Vasil Mico, Raymond Comenzo, Shahzad Raza, Jason Valent, Faiz Anwer, Christy Samaras, Louis Williams, Jack Khouri, Xia Wu, Parva Bhatt, Andreas Klein, Joslyn Rudoni, Teresa Fogaren, Mikhaila Rice, Jonathan Kissam, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2025-3961

Published: 2025

Journal Articles

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Blood (2025) 146 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2025-4601

Published: 2025

Journal Articles

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Blood (2025) 146 (Supplement 1): 4579.

https://doi.org/10.1182/blood-2025-4579

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience

Hossam M. Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Asfand Yar Cheema, Louis Williams, Diana Basali, Christy Samaras, Beth Faiman, Willem van Heeckeren, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Jason Valent, Shahzad Raza

Blood (2025) 146 (Supplement 1): 6367.

https://doi.org/10.1182/blood-2025-6367

Published: 2025

Journal Articles

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Blood (2025) 146 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2025-6350

Published: 2025

Journal Articles

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 720.

https://doi.org/10.1182/blood-2025-720

Published: 2025

Journal Articles

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2025-5802

Published: 2025

Journal Articles

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria Nachar

Blood (2024) 144 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2024-193025

Published: 2024

Journal Articles

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Yara Shatnawi, Zainab Motiwala, Faiz Anwer, Danai Dima, Louis S Williams, Nausheen Ahmed, Sandra Mazzoni, Jack Khouri, Joslyn Rudoni, Mikhaila Rice, Diana Basali, Christy J. Samaras, Jason Valent, Al-Ola Abdallah, Tara Roy, Beth M. Faiman, Shahzad Raza

Blood (2024) 144 (Supplement 1): 7044.

https://doi.org/10.1182/blood-2024-212202

Published: 2024

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Danai Dima, James A Davis, Aliya Rashid, Mikhaila Rice, Shaun DeJarnette, Leyla Shune, Jack Khouri, Shahzad Raza, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2023-181331

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Heena P Kurish, Kerri Row, Austin Kurkowski, Mikhaila Rice, Joslyn Rudoni, Jack Khouri, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Willem van Heeckeren, Jason Valent, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12496–12497.

https://doi.org/10.1182/blood-2022-162821

Published: 2022

Journal Articles

Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients

Hussein Awada, Adel Hajj Ali, Danai Dima, Lauren M. Granat, Michael Sheu, Puneet Dhillon, Mikhaila Rice, Heena P Kurish, Louis S. Williams, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10583–10584.

https://doi.org/10.1182/blood-2022-165673

Published: 2022

Journal Articles

Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Danai Dima, Lauren M. Granat, Michael Sheu, Puneet Dhillon, Mikhaila Rice, Heena P Kurish, Louis S. Williams, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 7217–7218.

https://doi.org/10.1182/blood-2022-165777

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients

Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only